GlassScriptPhysician profile
Gary G Williams
NPI 1306801626
$4,557.56
in general payments reported to CMS, 2019-2025
29 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $139 · 2021: $457 · 2022: $474 · 2023: $866 · 2024: $983 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,031.36 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $768.84 | 2019-2025 | |
| Abbvie INC. | $508.24 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $409.19 | 2019-2025 | Prolia, Evenity, Tezspire |
| Novo Nordisk INC | $399.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $246.70 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $192.31 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $148.50 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $132.20 | 2019-2025 | |
| Amarin Pharma, INC. | $124.64 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $71.61 | 2019-2024 | |
| Esperion Therapeutics, INC. | $65.03 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.08 | 2025 | Caplyta |
| Radius Health, INC. | $45.34 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2020-2024 | Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.33 | 2021-2023 | Freestyle Libre 2 |
| Kyowa Kirin, INC. | $38.02 | 2025 | |
| Dexcom, INC. | $34.75 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Idorsia Pharmaceuticals US INC | $26.99 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $26.16 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $23.96 | 2024-2025 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $20.42 | 2025 | |
| Merck Sharp & Dohme LLC | $16.60 | 2023 | Verquvo, Lagevrio, Belsomra |
| Xeris Pharmaceuticals, INC. | $16.44 | 2025 | Recorlev |
| Sumitomo Pharma America, INC. | $13.86 | 2025 | Gemtesa |
| Boston Scientific Corporation | $13.10 | 2021 | |
| Axsome Therapeutics, INC. | $13.07 | 2024 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $12.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.